As a result, Shandong Weigao will become the single largest shareholder of Biosensors with 370 million

shares, or approximately 21.6% of the Company

is this a good new?? more cheap share in chinese hand to play with.

  ‐ Biosensors International Group, Ltd. (“Biosensors”, “Company”,‐ owned subsidiary of Weigao‐ owned subsidiary of Shandong Weigao

Reasons for takeover bid for BIG soon

Japan

Terumo   Japan   capture 50% of the mkt.of jappan . Morever J& J in Japan is no more in stent buisness. Now stand at USD 80 million for japan  and USD 250 for worldwide

 

China

 

With completion of  acquisition of  JWMS and having Shandong Weigao become one of the keyshare holder will strengthen the company long term position in china   world fastest growing DES market

 

All set to grow it market share in china .

 

BioMatrix Flex’s approval for sale in China will be a longer term Catalyst for BIG now a done deal ,a 5% market  share will add another 8% to FY12F revenue



 

Rest of world except USA

 

Des Market expect to grow by 20% yearly

 

The group’s balance sheet has improved significantly with
shareholders’ funds expanding to USD1bn and cash rising to more than
USD200mn.

So  biggest market in world   USA  is open to winner of  takeover of BIG.

 

NEWS RELEASE

BioFreedom™ FIM Trial Demonstrates Comparable Long-Term Safety and Efficacy

to Conventional Drug-Eluting Stent

San Francisco, USA, 10 November 2011

BioFreedom represents the latest development in Biosensors’ stent technology, featuring a micro-structured abluminal surface which permits the controlled release of Biolimus A9™ (BA9™) without the use of a polymer. BA9 is a highly lipophilic antirestenotic drug developed by Biosensors specifically for use with stents. Two versions of the stent were studied in this trial: one with a drug dosage of 15.6 μ g/ per mm of stent length (standard dose) - the same as that used in BioMatrix Flex™ and the other with a drug dosage of 7.8 μ g/ per mm of stent length (low dose).

182 patients were equally randomized into three treatment groups: BioFreedom standard dose (SD) BioFreedom low dose (LD) and Taxus Liberté. 99% of enrolled patients were followed up at two years.

The rate of MACE (a composite of all death, MI, emergent cardiac artery bypass graft (CABG) and target lesion revascularization (TLR)) observed in patients treated with BioFreedom SD was numerically lower than that observed in patients treated with Taxus Liberté (6.8% vs. 10.0%: p=0.54). TLR was performed half as often on patients treated with BioFreedom SD as those treated with Taxus Liberté (3.4% vs. 6.7% p=0.42).

Both BioFreedom SD and BioFreedom LD demonstrated sustained safety up to two years, including absence of stent thrombosis.

" The results from this study are very significant as they demonstrate that a polymer free drug-coated stent is as safe and efficacious as a conventional drug-eluting stent with a durable polymer coating over a two-year period" , commented Professor Grube. " I am excited about the concept of a polymer-free stent, as the rapid drug clearance and absence of a polymer drug carrier could promote more rapid vessel healing and ultimately reduce the need for longer term dual anti-platelet therapy. A larger study is now required to confirm these encouraging findings." Page - Biosensors International Group, Ltd. (" Biosensors" , " Company" , Bloomberg: BIG SP) announced two-year results from the BioFreedom first in man (FIM) trial, which showed similar clinical outcomes between BioFreedom™, a polymer-free drug-coated stent (" DCS" ), and Boston Scientific’s Taxus™ Liberté™ drug-eluting stent (DES). There was no evidence of stent thrombosis in either trial arm. Results were presented by Professor Eberhard Grube, University Hospital Bonn, Germany, at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. 2 of 3

" These latest results confirm that Biosensors continues to lead the industry in stent innovation, trailblazing first with biodegradable polymer technology and now with polymer-free technology" , added Jeffrey B. Jump, Co-CEO of Biosensors. " Based on these positive results, we have committed to a major follow-on study assessing the potential for BioFreedom to reduce the need for dual anti-platelet therapy, working closely with the Center of European Cardiovascular Research (CERC)" .

BioFreedom FIM is a prospective, multi-centre study involving 182 patients with symptomatic ischemic heart disease. It involves a first cohort of 75 patients, evaluated for in-stent late lumen loss at four months, and a second cohort of 107 patients, evaluated at 12 months. The primary endpoint of BioFreedom FIM was in-stent late lumen loss at 12 months in the second cohort. Results from the first cohort, showing four-month non-inferiority of late lumen loss between BioFreedom and Taxus Liberté, were presented at TCT in 2009. Twelve-month data from the second cohort was presented at TCT in 2010, in which BioFreedom SD demonstrated similar efficacy, measured by late lumen loss, compared with Taxus Liberté (p

The clinical status of the patients in the trial is being followed up out to five years and reported annually. non-inferiority = 0.001), with a trend towards superiority (psup = 0.11).

 

BioMatrix Flex™ Improves Long-Term Clinical Outcomes Compared to Cypher® Select™ The Lancet

San Francisco, USA, 9 November 2011 - Biosensors International Group, Ltd. (" Biosensors" , " Company" , Bloomberg: BIG SP) has announced four-year results of the LEADERS trial, showing improved long-term clinical outcomes for BioMatrix Flex™, Biosensors’ Biolimus A9™-eluting stent system with abluminal biodegradable polymer, compared to Cypher® Select™, Johnson & Johnson’s sirolimus-eluting stent system with a durable polymer. This improvement was mainly achieved by reducing the risk of cardiac events associated with very late stent thrombosis (VLST) occurring beyond the first year of follow-up. Results were presented yesterday by Professor Thomas A. Ischinger, Kardiologie im Zentrum, Munich, Germany, at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. The results were simultaneously published online by The Lancet.1

" These findings provide the basis for the proof of concept of biodegradable polymer drug-eluting stents" , commented Principle Investigator Professor Stephan Windecker, University Hospital, Bern, Switzerland. " They are the first evidence of a difference in stent thrombosis translating into a difference in clinical outcomes."

There was an excellent follow-up rate of over 96% at four years, at which time the risk of MACE (Major Adverse Cardiac Events) was lower in patients treated with BioMatrix Flex than in those treated with Cypher Select (18.7% vs. 22.6%: p = 0.050). The benefit of BioMatrix Flex appeared more pronounced between years one and four. During this one to four year period, BioMatrix Flex was also associated with an 80% relative risk reduction in terms of definite VLST compared with Cypher Select.

An analysis of the correlation between MACE and definite stent thrombosis events showed that the benefit in favor of BioMatrix Flex in terms of MACE was largely driven by a lower risk of MACE associated with definite VLST beyond the first year of follow-up.

" We are very encouraged by these results, which further support the long-term patient benefit of BioMatrix Flex" , added Jeffrey B. Jump, Co-CEO of Biosensors. " LEADERS has been given further credibility by the fact that results have now been simultaneously published in

The initial results from LEADERS, presented at the European Society of Cardiology (" ESC" ) congress in 2008 and simultaneously published in The Lancet, demonstrated BioMatrix Flex to be non-inferior to Cypher Select in respect of the primary endpoint, incidence of MACE at nine months. This non-inferiority was confirmed in the one, two and three year results, during which time a diverging trend towards a safety benefit for BioMatrix Flex was observed.

Reference

1 Stefanini GG, Kalesan B, Serruys PW et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. The Lancet, Early Online Publication, 9 November 2011. doi:10.1016/SO140-6736(11)61672-3

Sponsored by Biosensors, LEADERS was independently designed, implemented and analyzed by the study investigators. Data management and analysis were performed by an independent academic institution. The Lancet twice, which must be a first for a drug-eluting stent study" .

Four-Year Results Simultaneously Published by